Gut Bacterium Regulates Cholesterol Levels in Mice
Researchers find that the bacterium Bacteroides uniformis helps lower cholesterol by producing a liver-targeting acid.
Updated on Oct. 24, 2026 in Life Sciences
Live Poll
Do you believe treatments derived from gut bacteria will be safer or more effective than traditional drugs?
Published on October 7, 2026, a new study identifies a gut bacterium capable of reducing atherosclerosis plaque in mice by up to 50%. This biological mechanism offers a potential new avenue for treatment as statin alternatives.
Why it matters
Statins have historically faced challenges with low long-term adherence, creating a need for more effective or easier-to-manage cholesterol therapies. This discovery targets the same liver pathways as traditional medications but through gut-microbe interactions.
The study utilized Bacteroides uniformis to produce pentadecanoic acid, which inhibits the HMG-CoA reductase enzyme. This process forced liver cells to increase LDL receptors, effectively extracting more cholesterol from the blood compared to baseline levels.
The players
Nature
This is a peer-reviewed scientific journal that publishes high-impact research across a wide range of scientific and technical disciplines.
National Centre for Cell Science
This is an Indian government-supported research organization located in Pune that focuses on cell biology and microbiology.
Stanford Medicine
This is a major academic medical center and research institution known for its advancements in biotechnology and clinical health studies.
The details
By blocking the HMG-CoA reductase enzyme, the bacterium forces the liver to clear LDL cholesterol from the bloodstream more efficiently. The research highlights a clear genetic link, as individuals with elevated blood fats consistently show lower concentrations of the specific acid produced by this bacterium.
Timeline
October 7, 2026: The study on Bacteroides uniformis was published in Nature.
August 2026: Researchers identified 14 new gut bacterial species in India.
March 2026: Stanford researchers traced a gut bacteria link to memory loss.
January 2026: Trial results for gut-microbe immunotherapy were reported.
1970s: Statins were first isolated from fungi.
The Big Picture
This discovery marks a significant scientific shift from the 1970s isolation of statins, which have long served as the standard for cholesterol management. By shifting focus toward gut-microbe interactions, the research challenges the reliance on synthetic enzyme inhibitors.
While currently limited to mouse models, the research points toward future oral treatments that could supplement or replace traditional statin regimens for patients. These therapies might eventually offer higher adherence rates by utilizing natural gut-based biological processes.
The takeaway
The research highlights that the composition of human gut bacteria is fundamentally linked to metabolic health and cholesterol regulation. Future human trials will be essential to determine if these microbial therapies can effectively translate into viable clinical health interventions.
Further reading
Explore more scientific advancements in Life Sciences.
Source note: This article includes information reported by Hindustan Times.
Live Poll
Do you believe treatments derived from gut bacteria will be safer or more effective than traditional drugs?
